KERX Related Analyst PT Change
-
Oppenheimer Lifs PT on Keryx Biopharmaceuticals (KERX) to $11
-
Stifel Nicolaus Boosts Keryx Biopharmaceuticals (KERX) PT to $13
-
Burrill Lifts PT on Keryx Biopharmaceuticals (KERX) to $11
-
Keryx Biopharmaceuticals (KERX) Gets Another 'Going to $15' Call
-
Roth Capital Doubles PT on Keryx (KERX); Sees Another 200% Upside
-
Roth Capital Upgrades Keryx Biopharmaceuticals (KERX) to Buy
-
Brean Murray Maintains 'Buy' on Keryx (KERX); Focus Shifts to Less Risky Zerenex
-
Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
Back to KERX Stock Lookup
